Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aroa Biosurgery
Hyperfine Says Question Is When, Not If, Portable MRI Will Impact The World; CEO Dave Scott Discusses
Hyperfine, which markets the first US FDA-cleared portable MRI system, is facing COVID-related headwinds in bringing its system to hospitals, but CEO Dave Scott says wider adoption of the disruptive solution is inevitable. The company is going public today after combining with the HealthCor Catalio Acquisition Corp.
Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.
Complete list of 103 domestic and 66 foreign device quality-related warning letters released in 2012.
With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Mesynthes Ltd